Panax Matrix is currently evaluating plans to develop an affordable formulation of Semaglutide for the Indian market. The initiative is part of the company’s broader vision to improve access to advanced therapies for the management of type 2 diabetes and obesity. The company is in the early stages of feasibility assessment, focusing on formulation strategies, sourcing, and regulatory pathways while ensuring adherence to quality and compliance standards.